OptimizeRx Down Over 17%, on Pace for Largest Percent Decrease Since November 2024 -- Data Talk

Dow Jones11-08

OptimizeRx Corporation ( OPRX ) is currently at $15.69, down $3.25 or 17.16%

 

--Would be lowest close since Aug. 20, 2025, when it closed at $15.49

--On pace for largest percent decrease since Nov. 14, 2024, when it fell 33.98%

--Currently down four of the past five days

--Currently down two consecutive days; down 18.11% over this period

--Worst two day stretch since the two days ending Nov. 15, 2024, when it fell 37.8%

--Down 23.43% this week; worst weekly performance since the week ending Nov. 15, 2024, when it fell 39.09%

--Down 23.43% month-to-date

--Up 222.84% year-to-date; on pace for best year since 1999, when it rose 1600%

--Down 99.99% from its all-time closing high of $106249.23 on May 17, 2005

--Up 149.84% from 52 weeks ago (Nov. 8, 2024), when it closed at $6.28

--Down 27.63% from its 52-week closing high of $21.68 on Oct. 24, 2025

--Up 310.2% from its 52-week closing low of $3.83 on Nov. 15, 2024

--Traded as low as $15.01; lowest intraday level since Aug. 8, 2025, when it hit $14.31

--Down 20.75% at today's intraday low; largest intraday percent decrease since Nov. 14, 2024, when it fell as much as 35.77%

 

All data as of 11:05:27 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

November 07, 2025 11:08 ET (16:08 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment